drugset / Trial / NCT00825500

Staccato Loxapine in Migraine (Out Patient)

NCT00825500

Phase 2 Completed 366 enrolled Alexza Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

Assess the safety and efficacy of Staccato Loxapine in patients with moderate to severe migraine headache with or without aura in an outpatient setting.

Timeline

Start
2009-01
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator loxapine Small molecule 1.25 mg Inhaled
Comparator loxapine Small molecule 2.5 mg Inhaled

Indications